=> d que
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE
L3 4 SEA FILE=REGISTRY SSS FUL L1
L4 4 SEA FILE=CAPLUS ABB=ON PLU=ON L3

=> d ibib abs hitstr 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:866796 CAPLUS
DOCUMENT NUMBER: 137:363037
TITLE: F-15078 and its salts from Phoma sp. SANK 13899 strain as new antimycotic agents
INVENTOR(S): Inukai, Masatoshi; Takatsu, Toshio; Yano, Tatsuya; Tanaka, Isshin
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002326952	A2	20021115	JP 2002-52496	20020228

PRIORITY APPLN. INFO.: JP 2001-56197 A 20010301
GI



I

AB F-15078 (I; R = H, COCH3) from Phoma sp. SANK 13899 strain and its salts are claimed as new antimycotic agents. The physicochem. property of I from 1H-NMR, HPLC, and FAM-MS were given. Capsules contg. I were formulated and antimycotic activity of I against Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans was tested.

IT **328298-26-6DP**, salts **328298-26-6P 328298-28-8DP**
, salts **328298-28-8P**
RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(F-15078 and its salts from Phoma sp. SANK 13899 strain as new antimycotic agents)

RN 328298-26-6 CAPLUS

CN Leucine, N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methylleucyl-L-threonyl-N-methylvalylalanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RN 328298-26-6 CAPLUS

CN Leucine, N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methylleucyl-L-threonyl-N-methylvalylalanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RN 328298-28-8 CAPLUS
CN Leucine, N-acetyl-N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methylleucyl-L-threonyl-N-methylvalylalanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RN 328298-28-8 CAPLUS
CN Leucine, N-acetyl-N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methylleucyl-L-threonyl-N-methylvalylalanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:833499 CAPLUS
DOCUMENT NUMBER: 137:336794
TITLE: Compounds having antifungal activity
INVENTOR(S): Yano, Tatsuya; Inukai, Masatoshi; Takatsu, Toshio; Tanaka, Isshin
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of Appl. No. PCT/JP00/05937.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160946	A1	20021031	US 2002-87633	20020301
WO 2001018227	A1	20010315	WO 2000-JP5937	20000831
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2001139597	A2	20010522	JP 2000-261990	20000831
EP 1209240	A1	20020529	EP 2000-956859	20000831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.:

JP 1999-249959	A	19990903
EP 2000-956859	A	20000831
JP 2000-261990	A	20000831
WO 2000-JP5937	A2	20000831
NO 2000-20021026	A	20020301

AB Cyclic depsipeptides which exhibit antifungal activity and are useful in treating and preventing fungal infectious diseases is claimed.

IT **328298-26-6P 328298-28-8P**
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(cyclic depsipeptide having antifungal activity produced by fermn.)

RN 328298-26-6 CAPLUS

CN Leucine, N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methylleucyl-L-threonyl-N-methylvalylalanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RN 328298-28-8 CAPLUS

CN Leucine, N-acetyl-N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-

methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methylleucyl-L-threonyl-N-methylvalylalanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:686516 CAPLUS
DOCUMENT NUMBER: 137:231477
TITLE: Novel antifungal antibiotics F-15078C and F-15078D, and their production
INVENTOR(S): Yoshida, Azusa; Takatsu, Toshio; Yano, Tatsuya; Tanaka, Isshin
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002255996	A2	20020911	JP 2001-51492	20010227

PRIORITY APPLN. INFO.: JP 2001-51492 20010227

AB Disclosed are novel compds. F-15078C and F-15078D, and their salts, having antifungal activity, suitable for use in a pharmaceutical compn. for treatment of fungal infection. The prodn. method of F-15078C and F-15078D from Phoma sp., esp SANK 13899 (FERM BP-6851) are also disclosed. A compd. F-15078C obtained from fermn. product of Phoma sp. SANK 13899 showed antifungal activity against Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans. A capsule contg. F-15078C 30, lactose 170, corn starch 150, and magnesium stearate 2 mg was prepd.

IT **458523-28-9P**, F 15078C **458523-29-0P**, F 15078D

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel antifungal antibiotics F-15078C and F-15078D)

RN 458523-28-9 CAPLUS

CN L-Leucine, N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-valyl-N-methyl-L-leucyl-L-threonyl-N-methyl-L-valyl-L-alanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 458523-29-0 CAPLUS

CN L-Leucine, N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methyl-L-leucyl-L-seryl-N-methyl-L-valyl-L-alanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:185938 CAPLUS
DOCUMENT NUMBER: 134:206668
TITLE: Antifungal compound F-15078
INVENTOR(S): Yano, Tatsuya; Inukai, Masatoshi; Takatsu, Toshio; Tanaka, Isshin
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018227	A1	20010315	WO 2000-JP5937	20000831
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
BR 2000013741	A	20020521	BR 2000-13741	20000831
EP 1209240	A1	20020529	EP 2000-956859	20000831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NZ 517561	A	20030630	NZ 2000-517561	20000831
AU 767250	B2	20031106	AU 2000-68674	20000831
NO 2002001026	A	20020409	NO 2002-1026	20020301
US 2002160946	A1	20021031	US 2002-87633	20020301

PRIORITY APPLN. INFO.:
JP 1999-249959 A 19990903
EP 2000-956859 A 20000831
JP 2000-261990 A 20000831
WO 2000-JP5937 W 20000831
NO 2000-20021026 A 20020301

GI



I R=H
II R=acetyl

AB The antifungal compd. F-15078A (I) and B (II) are manufd. with Phoma sp. SANK13899 by fermn. I and II are useful for prevention and control of fungal infections. Shake culture of Phoma and isolation of the antifungal F-15078 from the fermn. broth and mycelium, resp., by solvent extn. and chromatogs. were shown. The physiol. and morphol. characteristics of the Phoma and physicochem. characteristics of I and II were also given.

IT **328298-26-6P**, Antifungal F 15078A **328298-28-8P**, Antifungal F 15078B
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antifungal compd. F-15078)

RN 328298-26-6 CAPLUS

CN Leucine, N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methylleucyl-L-threonyl-N-methylvalylalanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.



PAGE 1-B



RN 328298-28-8 CAPLUS
CN Leucine, N-acetyl-N-methyl-L-isoleucyl-L-threonyl-2-hydroxy-3-methylbutanoyl-2-hydroxy-4-methylpentanoyl-L-isoleucyl-N-methylleucyl-L-threonyl-N-methylvalylalanyl-N-methyl-, (10.fwdarw.2)-lactone (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT